These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1489882)

  • 1. An appraisal of spontaneous adverse event monitoring.
    Fletcher AP
    Adverse Drug React Toxicol Rev; 1992; 11(4):213-27. PubMed ID: 1489882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient reporting of adverse drug reactions: useful information for pain management?
    Jarernsiripornkul N; Krska J; Richards RM; Capps PA
    Eur J Pain; 2003; 7(3):219-24. PubMed ID: 12725844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
    Lilienfeld DE
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of adverse drug reactions: from diagnosis to signal.
    Edwards IR
    Therapie; 2001; 56(6):727-33. PubMed ID: 11878098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
    Benjamin DM; Pendrak RF
    J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The incidence of drug side effects with reference to organ systems. Experience of the spontaneous reporting system of the Swiss Drug Side Effect Center and Comprehensive Drug Monitoring].
    Kuhn M; Hartmann K; Maibach R; Capaul R; Gartmann JC
    Ther Umsch; 1993 Jan; 50(1):8-12. PubMed ID: 8378869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for the future conduct of pharmacovigilance.
    Waller PC; Evans SJ
    Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 19. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.
    Takata GS; Mason W; Taketomo C; Logsdon T; Sharek PJ
    Pediatrics; 2008 Apr; 121(4):e927-35. PubMed ID: 18381521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.